e.l.f. Beauty stock plummets 20% as revenue and guidance fall short of expectations
Investing.com - RBC Capital has reiterated an Outperform rating on Karyopharm Therapeutics (NASDAQ:KPTI) with a price target of $19.00, citing positive outlook for the company’s selinexor treatment in myelofibrosis (MF). This target represents significant upside from the current price of $5.36, with InvestingPro data showing the stock is currently undervalued based on Fair Value estimates.
The investment firm noted that key opinion leaders expressed optimism about selinexor’s potential in frontline MF when used in combination with ruxolitinib, suggesting that nausea concerns could be managed with proper anti-emetic regimens and patient education.
RBC Capital affirmed its belief that selinexor’s activity in myelofibrosis is genuine, though it acknowledged that demonstrating significant symptomatic benefits over ruxolitinib alone remains the biggest risk due to limited Phase I data and historical challenges.
The firm emphasized that with runway concerns now addressed and potential endometrial cancer data expected later next year, Karyopharm’s risk-reward profile heading into the Phase III readout remains "very attractive."
RBC’s $19.00 price target suggests substantial upside potential for Karyopharm shares, which have been trading significantly below this level in recent sessions.
In other recent news, Karyopharm Therapeutics Inc. reported a 13.4% increase in total revenue for the third quarter of 2025, reaching $44 million. Despite this revenue growth, the company faced a net loss of $33.1 million, resulting in an earnings per share (EPS) of -$3.82. The mixed financial results have been noted by analysts and investors. Analyst firms have yet to provide an updated rating or outlook following these earnings results. These developments are part of the broader financial landscape for Karyopharm as it navigates its fiscal challenges. Investors are watching closely to see how the company will address its current financial situation. The recent earnings report highlights both the potential and the hurdles facing Karyopharm in its future financial planning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.